Navigation Links
Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
Date:5/29/2013

DALLAS, May 29, 2013 /PRNewswire-iReach/ -- Global Alzheimer's Drugs Market 2012-2016, Alzheimer's Disease Therapeutics and Diagnostics: Global Markets and Alzheimer Disease Treatment Drugs Markets in China are new market research reports available with RnRMarketResearch.com.

(Photo: http://photos.prnewswire.com/prnh/20130529/CG21228)

Global Alzheimer's Drugs market is forecast to grow at a CAGR of 3.26% over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Alzheimer's Drugs market has also been witnessing the availability of improved diagnostics. However, numerous patent expiries could pose a challenge to the growth of this market. Alzheimer's disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients climb and the frustration with lack of effective treatments grows. Though there are a number of marketed drugs approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, there are now numerous companies developing novel treatments.

The report Global Alzheimer's Drugs Market 2012-2016 covers the worldwide Alzheimer's drugs market in the Americas, the EMEA, and the APAC regions, its market landscape, and growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market including but not limited to Eisai Co., Ltd., Forest Laboratories Inc., H. Lundbeck A/S., Novartis AG, and Pfizer Inc. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=98045.

The scope of the report Alzheimer's Disease Therapeutics and Diagnostics: Global Markets is on the pharmaceutical segment, diagnostics and imaging modalities. It is a compiled study of the market, and current and emerging modes of treatment. The research presents the market segment's economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2012 to 2017. It also projects usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will be of interest also to suppliers of products and services to this market area. The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=96663.

China's demand for alzheimer disease treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. The new research Alzheimer Disease Treatment Drugs Markets in China examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. Production, demand, sales volume and more for the following have been covered in this report: Ginkgo Bilota Extract, Breviscapine, Ganglioside, Donepezil, Galanthamine, Nicergoline, Rivastigmine, Memantine, Huperzine A,  Oxiracetam, Flunarizine and Piracetam. Buy / Order a copy of this report at 50% discount http://www.rnrmarketresearch.com/contacts/purchase?rname=90552 – listed price is $4000 for a single user license – the same can be availed for US$2000; kindly contact sales@rnrmarketresearch.com with your request for this discounted pricing.

Explore more reports on Alzheimer Drugs and related markets @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/alzheimer-drugs.

About Us:

RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Explore multi-industry reports targeted at geographies across the globe @ http://marketreportsstore.com/. We also have business intelligence and competitive analysis studies focused on multiple industries in China available @ http://www.marketreportschina.com/.

Media Contact:

Priyank Tiwari RnR Market Research, +1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE RnR Market Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
2. New Alzheimers Treatment Protocol Produces Significant Results
3. Ceregene And Alzheimers Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial
4. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
5. NeuroQuest Close to Validation Trial for Biomarker Platform in Diagnosis of Alzheimers
6. New Long-Term Study Suggests Lower Mortality in Alzheimers Patients Treated with Galantamine Versus Placebo
7. Research Published in European Journal of Pharmacology Shows that Star Scientifics Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimers Disease and in Blood
8. Innovative Drugs to Transform European Alzheimers Disease Medication Market by 2015, Says Frost & Sullivan
9. World Alzheimers Report 2012 Reveals Stigma and Social Exclusion are Major Barriers for People With Dementia and Their Carers
10. New International Survey Reveals Multiple Barriers to an Accurate and Timely Alzheimers Disease Diagnosis
11. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):